Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers
Authors:
- Francisco Javier RamosFRFrancisco Javier Ramos
- Teresa MacarullaTMTeresa Macarulla
- Elena ElezEEElena Elez
- Manuel Ruiz-EcharriMRManuel Ruiz-Echarri
- Jose Perez-GarciaJPJose Perez-Garcia
- Josep TaberneroJTJosep Tabernero
- 1 July 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 21 (4) , 374-380
Abstract
In the last years, interesting advances have been reported in the treatment of infrequent digestive tumors. The increasing development of new targeted therapies in human cancer has also impacted in these rare gastrointestinal malignancies providing a wide range of possibilities in the design of future clinical trials. The inhibition of angiogenesis and the blockage of the epidermal growth factor receptor pathway have provided the most interesting activity in recently reported studies for esophageal and biliary tract carcinomas. Additionally, several targeted therapies have been developed to target the main kinase proteins of the most important pathways of these malignancies. The results of the biggest phase III trial in locally advanced anal carcinoma have been recently published. Finally, the inhibition of epidermal growth factor receptor has also showed promising activity in anal carcinomas. Recent advances in the knowledge of molecular mechanism of carcinogenesis have led to meaningful changes in the management of gastrointestinal cancers. Although the major advances in targeted therapy have been introduced in the treatment of colorectal cancer, new interesting approaches have been reported in less frequent gastrointestinal tumors such as esophageal, biliary tract, and anal canal carcinoma opening a new hope in the treatment of these rare tumors in the molecular targeted therapy era.Keywords
This publication has 59 references indexed in Scilit:
- Pilot Study of Gefitinib, Oxaliplatin, and Radiotherapy for Esophageal AdenocarcinomaAmerican Journal of Clinical Oncology, 2008
- Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal (GE) junction carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas-SouthwesternJournal of Clinical Oncology, 2008
- HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trialJournal of Clinical Oncology, 2008
- Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of ToxicityInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical ResponseClinical Cancer Research, 2007
- Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomasCancer, 2007
- Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127Journal of Clinical Oncology, 2006
- Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancerJournal of Clinical Oncology, 2006
- Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer PatientsJournal of Clinical Oncology, 2006
- Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I studyAnti-Cancer Drugs, 2006